This is the authors' abstract. We don't add key points for this paper.
Real world data are advocated as an alternative approach to RCTs for closing knowledge gaps on drugs, but Beate Wieseler and colleagues argue that this approach is the wrong remedy for current challenges in drug development
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wieseler et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: